Table 1.
Serum BDNF levels in stroke patients with a systolic blood pressure lower or higher than 160 mmHg at the admission.
Table 2.
Population characteristics in non-treated and in rt-PA treated patients.
Fig 1.
Serum BDNF levels in stroke patients assessed at D0 (admission), D1, D7 (non-treated, n = 11 and rt-PA-treated, n = 18) and D90 (non-treated, n = 8 and rt-PA-treated, n = 12) after ischemic stroke.
Values are expressed as mean ± SEM. a Differences between the two groups of patients were analyzed at the different time points using the non-parametric Mann–Whitney-U test with significance set at (*) p <0.05.
Table 3.
Comparison of platelet counts in stroke patients treated or not with rt-PA.
Table 4.
t-PA/plasmin activity in serum of stroke patients.
Table 5.
Correlations between serum BDNF and t-PA/plasmin activity in stroke patients.
Table 6.
NIHSS score reduction between non-treated and rt-PA-treated patients over periods ranging from D0 to D1, D0 to D7 and D0 to D90.
Table 7.
Correlations between NIHSS score variations over periods ranging from D0 to D1, D0 to D7 and D0 to D90 and serum BDNF levels in stroke patients at D0, D1, and D7.
Table 8.
Correlation between serum BDNF and cardiovascular score in stroke patients.
Fig 2.
Comparison of serum BDNF levels in stroke rats treated or not with rt-PA.
BDNF levels were assessed before and after (1h, 4h and 24h) photothrombotic stroke induction. Values are expressed as mean ± SEM. aDifferences between two groups of rats were analyzed at the different time points using the non-parametric Mann–Whitney-U test with significance set at (*) p <0.05.
Table 9.
Correlations between serum BDNF levels and t-PA/plasmin activity in stroke rats.